Sarcoma & GIST
From the Journals
TKIs and immunotherapy hold promise for alveolar soft part sarcoma
Tyrosine kinase inhibitors and immune checkpoint inhibitors show encouraging results in the treatment of alveolar soft part sarcoma
Conference Coverage
Predicting treatment response in leiomyosarcoma, liposarcoma
Aberrations in oncogenic pathways and immune modulation influence treatment response in patients with metastatic leiomyosarcoma or liposarcoma.
News
FDA lifts partial hold on tazemetostat trials
The partial hold that paused U.S.-based enrollment in clinical trials of tazemetostat has been lifted.
Education Center
Improved survival in liposarcoma
From the Journals
PARP inhibitor plus trabectedin shows promise for sarcoma
Investigators planning phase 2 studies after phase 1b results demonstrated tolerability and efficacy with the combination of olaparib and...
From the Journals
HIV-associated Kaposi sarcoma responds to checkpoint inhibitors
Checkpoint inhibitor therapy is effective for patients with HIV-associated Kaposi sarcoma (KS), a recent study has found.
Partial or...
Journal Club
Novel molecular assay: Promising results in bone and soft tissue tumor evaluation
Two new fusion partners for the USP6 gene were found using AMP-based targeted next-generation sequencing.
Conference Coverage
SEAL: Selinexor extends PFS in advanced dedifferentiated liposarcoma
The statistical significance of the improvements varied depending on how progression-free survival was measured.
From the Journals
Chromoplexy linked to aggressive Ewing sarcomas
Analysis of the sequence context surrounding chromoplexy breaks may provide clues and potentially point to a therapeutic vulnerability that could...
New Therapies
Addressing the rarity and complexities of sarcomas
Conference Coverage
Lurbinectedin shows activity against relapsed Ewing’s
CHICAGO – The agent blocks DNA transcription and induces double-strand breaks leading to apoptosis; results warrant further exploration,...